PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease
- PMID: 34411390
- PMCID: PMC9290825
- DOI: 10.1002/humu.24275
PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease
Abstract
Mutations in PRPH2, encoding peripherin-2, are associated with the development of a wide variety of inherited retinal diseases (IRDs). To determine the causality of the many PRPH2 variants that have been discovered over the last decades, we surveyed all published PRPH2 variants up to July 2020, describing 720 index patients that in total carried 245 unique variants. In addition, we identified seven novel PRPH2 variants in eight additional index patients. The pathogenicity of all variants was determined using the ACMG guidelines. With this, 107 variants were classified as pathogenic, 92 as likely pathogenic, one as benign, and two as likely benign. The remaining 50 variants were classified as variants of uncertain significance. Interestingly, of the total 252 PRPH2 variants, more than half (n = 137) were missense variants. All variants were uploaded into the Leiden Open source Variation and ClinVar databases. Our study underscores the need for experimental assays for variants of unknown significance to improve pathogenicity classification, which would allow us to better understand genotype-phenotype correlations, and in the long-term, hopefully also support the development of therapeutic strategies for patients with PRPH2-associated IRD.
Keywords: LOVD; PRPH2; in silico assessment; inherited retinal disease; molecular genetics.
© 2021 The Authors. Human Mutation published Wiley Periodicals LLC.
Conflict of interest statement
The authors declare that there are no conflict of interests.
Figures
Similar articles
-
Genotype-phenotype associations in a large PRPH2-related retinopathy cohort.Hum Mutat. 2020 Sep;41(9):1528-1539. doi: 10.1002/humu.24065. Epub 2020 Jul 5. Hum Mutat. 2020. PMID: 32531846 Free PMC article.
-
PRPH2-Associated Retinopathy: Novel Variants and Genotype-Phenotype Correlations.Ophthalmol Retina. 2023 May;7(5):450-461. doi: 10.1016/j.oret.2022.12.008. Epub 2022 Dec 21. Ophthalmol Retina. 2023. PMID: 36563963
-
Current and Future Directions in Developing Effective Treatments for PRPH2-Associated Retinal Diseases: A Workshop Report.Transl Vis Sci Technol. 2024 Oct 1;13(10):16. doi: 10.1167/tvst.13.10.16. Transl Vis Sci Technol. 2024. PMID: 39382871 Free PMC article.
-
New Insight into the Genotype-Phenotype Correlation of PRPH2-Related Diseases Based on a Large Chinese Cohort and Literature Review.Int J Mol Sci. 2023 Apr 4;24(7):6728. doi: 10.3390/ijms24076728. Int J Mol Sci. 2023. PMID: 37047703 Free PMC article. Review.
-
Gene therapy for PRPH2-associated ocular disease: challenges and prospects.Cold Spring Harb Perspect Med. 2014 Aug 28;4(11):a017376. doi: 10.1101/cshperspect.a017376. Cold Spring Harb Perspect Med. 2014. PMID: 25167981 Free PMC article. Review.
Cited by
-
The Formation and Renewal of Photoreceptor Outer Segments.Cells. 2024 Aug 15;13(16):1357. doi: 10.3390/cells13161357. Cells. 2024. PMID: 39195247 Free PMC article. Review.
-
A new mouse model for PRPH2 pattern dystrophy exhibits functional compensation prior and subsequent to retinal degeneration.Hum Mol Genet. 2024 Nov 5;33(21):1916-1928. doi: 10.1093/hmg/ddae128. Hum Mol Genet. 2024. PMID: 39231530 Free PMC article.
-
ROM1 is redundant to PRPH2 as a molecular building block of photoreceptor disc rims.bioRxiv [Preprint]. 2023 Aug 29:2023.07.02.547380. doi: 10.1101/2023.07.02.547380. bioRxiv. 2023. Update in: Elife. 2023 Nov 22;12:RP89444. doi: 10.7554/eLife.89444 PMID: 37693615 Free PMC article. Updated. Preprint.
-
The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: A Narrative Review of Pathomolecular Mechanisms for the Development of Cell-Based Therapies.Biomedicines. 2023 Sep 28;11(10):2656. doi: 10.3390/biomedicines11102656. Biomedicines. 2023. PMID: 37893030 Free PMC article. Review.
-
Phenotypic variability in PRPH2 as demonstrated by a family with incomplete penetrance of autosomal dominant cone-rod dystrophy.Doc Ophthalmol. 2023 Jun;146(3):267-272. doi: 10.1007/s10633-022-09916-5. Epub 2023 Jan 7. Doc Ophthalmol. 2023. PMID: 36609934
References
-
- Abu‐Safieh, L. , Alrashed, M. , Anazi, S. , Alkuraya, H. , Khan, A. O. , Al‐Owain, M. , Al‐Zahrani, J. , Al‐Abdi, L. , Hashem, M. , Al‐Tarimi, S. , Sebai, M. A. , Shamia, A. , Ray‐Zack, M. D. , Nassan, M. , Al‐Hassnan, Z. N. , Rahbeeni, Z. , Waheeb, S. , Alkharashi, A. , Abboud, E. , … Alkuraya, F. S. (2013). Autozygome‐guided exome sequencing in retinal dystrophy patients reveals pathogenetic mutations and novel candidate disease genes. Genome Research, 23(2), 236–247. 10.1101/gr.144105.112 - DOI - PMC - PubMed
-
- Alapati, A. , Goetz, K. , Suk, J. , Navani, M. , Al‐Tarouti, A. , Jayasundera, T. , Tumminia, S. J. , Lee, P. , & Ayyagari, R. (2014). Molecular diagnostic testing by eyeGENE: Analysis of patients with hereditary retinal dystrophy phenotypes involving central vision loss. Investigative Ophthalmology and Visual Science, 55(9), 5510–5521. 10.1167/iovs.14-14359 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
